Boston Scientific Corporation (NYSE:BSX) TD Cowen 45th Annual Healthcare Conference March 4, 2025 9:10 AM ET
Company Participants
Dan Brennan – Chief Financial Officer
Ken Stein – Chief Medical Officer
Art Butcher – Executive Vice President, MedSurg and APAC
Conference Call Participants
Josh Jennings – TD Cowen
Josh Jennings
Good morning. I’m Josh Jennings from the TD Cowen Medical Devices research team, and joined by Brian Kennedy and Eric Anderson, and we’re excited to kick off Day 2 of the 45th Annual TD Cowen Healthcare Conference and thrilled to have executives from the Boston Scientific management team joining us and spending time with us this week.
Thank you, gentlemen, for this fireside chat.
Unidentified Company Representative
Great to be here.
Josh Jennings
Let me do quick introductions. We have from your left to right, most of you are familiar with Dan Brennan, Chief Financial Officer; Dr. Ken Stein, Chief Medical Officer; and Art Butcher, Executive Vice President, MedSurg and APAC.
Gentlemen, you guys have had a 10-plus year track record of outperformance if you just think of the overall CAGR and accelerating top line revenue growth, and that has been driven by improvement in the WAMGR and the playbook that you guys have run has been extremely effective and emulated by other large-cap medical device companies in the industry.
Question-and-Answer Session
Q – Josh Jennings
But I wanted to just maybe first start on, as I say, we talked a little bit about this last night at dinner, but just as you guys are approaching $20 billion in revenue, it gets a little bit tougher to grow at the pace that you’re currently growing, but you did announce earlier this year in a presentation that the WAMGR would increase again in 2026, get to 9%. You guys have consistently outpaced your markets.
